Samuel Backenroth
Net worth: 14 400 $ as of 29/04/2024
Profile
Samuel I.
Backenroth is the founder of Orphion Therapeutics, Inc., DepYmed, Inc. He previously worked as the Chief Financial Officer at Vascular Biogenics Ltd.
and Notable Labs Ltd.
From 2010 to 2019, he held the position of CFO, Secretary & Principal Accounting Officer at Ohr Pharmaceutical, Inc. In 2019, he served as the Chief Financial Officer, Secretary & Treasurer at Neubase Therapeutics, Inc. and NeuBase Therapeutics, Inc. Mr. Backenroth obtained his undergraduate degree from Touro College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.17% | 30/03/2023 | 15,000 ( 0.17% ) | 14 400 $ | 29/04/2024 |
Former positions of Samuel Backenroth
| Companies | Position | End |
|---|---|---|
| NEUBASE THERAPEUTICS, INC. | Director of Finance/CFO | 29/09/2021 |
Neubase Therapeutics, Inc. /Old/
 Neubase Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Neubase Therapeutics, Inc. develops peptide-nucleic acid antisense oligonucleotide platform. Its platform address repeat expansion disorders, with an initial focus on huntington’s disease and myotonic dystrophy, as well as other dominant genetic disorders. The company was founded by Dietrich A. Stephan and is headquartered in Pittsburgh, PA. | Director of Finance/CFO | 31/12/2020 |
Ohr Pharmaceutical, Inc.
 Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | Director of Finance/CFO | 31/12/2018 |
| NOTABLE LABS, LTD. | Director of Finance/CFO | - |
Training of Samuel Backenroth
| Touro College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NEUBASE THERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | Health Technology |
DepYmed, Inc.
 DepYmed, Inc. BiotechnologyHealth Technology DepYmed , Inc. is a cancer and rare disease therapeutic development company. The company is headquartered in Farmingdale, NY. | Health Technology |
Neubase Therapeutics, Inc. /Old/
Neubase Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Neubase Therapeutics, Inc. develops peptide-nucleic acid antisense oligonucleotide platform. Its platform address repeat expansion disorders, with an initial focus on huntington’s disease and myotonic dystrophy, as well as other dominant genetic disorders. The company was founded by Dietrich A. Stephan and is headquartered in Pittsburgh, PA. | Health Technology |
Orphion Therapeutics, Inc.
 Orphion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orphion Therapeutics, Inc. develops novel gene therapies for the treatment of genetic disorders. The private company is based in Great Neck, NY. The company was founded by Samuel I. Backenroth. The CEO is Jason Scott Slakter. | Health Technology |
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
- Stock Market
- Insiders
- Samuel Backenroth
